Improving Management of Patients at High Risk for Osteoporotic Fractures

This study is ongoing, but not recruiting participants.

First Received: August 29, 2005 Last Updated: September 26, 2005 History of Changes

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00139438

Purpose

The purpose of this study is to assess the impact of disease management interventions on percent receiving a bone densitometry test and percent appropriately prescribed a medication for osteoporosis.

Condition	Intervention
Osteoporosis	Behavioral: Disease Management Assessment

MedlinePlus related topics: Fractures Osteoporosis

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Educational/Counseling/Training, Randomized, Open Label, Placebo Control, Parallel Assignment
Official Title:	Improving Management of Patients at High Risk for Osteoporotic Fractures

Further study details as provided by Merck:

Primary Outcome Measures:

A composite measure of bone mineral density (BMD) testing and/or osteoporosis medications prescriptions.

Secondary Outcome Measures:

BMD testing, osteoporosis medication prescriptions, fracture

Estimated Enrollment:	4266
Study Start Date:	September 2004

Eligibility

Ages Eligible for Study:	45 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Members of the Horizon Blue Cross Blue Shield of New Jersey who are at risk for osteoporosis based on age (women age 65 or older, men and women age 45 or older who have a history of fragility fracture or have a history of taking oral glucocorticoids over 3 months).

Exclusion Criteria:

Individuals who are not members of Horizon Blue Cross Blue Shield of New Jersey and who otherwise do not meet the inclusion criteria.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00139438

Locations

United States, Massachusetts
Brigham and Woman's Hospital
Boston, Massachusetts, United States, 02120

Sponsors and Collaborators

Merck

Investigators

Principal Investigator:

Daniel H. Solomon, M.D., M.P.H.

Brigham and Woman's Hospital

More Information

No publications provided

Study ID Numbers:	2005_049
Study First Received:	August 29, 2005
Last Updated:	September 26, 2005
ClinicalTrials.gov Identifier:	NCT00139438 History of Changes
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Musculoskeletal Diseases
Fractures, Bone
Wounds and Injuries
Disorders of Environmental Origin

Fractures, Spontaneous
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases

Additional relevant MeSH terms:

Musculoskeletal Diseases
Fractures, Bone
Wounds and Injuries
Disorders of Environmental Origin

Fractures, Spontaneous
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases

ClinicalTrials.gov processed this record on May 07, 2009